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Purpose: The objective of this study was to evaluate the efﬁcacy and safety of Ahmed glaucoma valve
(AGV) implantation in Taiwanese patients with intractable glaucoma.
Methods: The study was a retrospective interventional case series conducted at a single institution
between January 2004 and January 2008 in Taiwan. The study population included 148 patients (148
eyes).
Results: The mean preoperative intraocular pressure (IOP) was 32.6  4.7 mmHg with medication (mean
number of medications was 3.4  1.0; range, 2e4). Postoperatively, the mean IOP declined signiﬁcantly
to 10.2 mmHg (range, 7e18 mmHg) on Day 1 (p < 0.01) and 17 mmHg (range, 15e23 mmHg) at the last
follow-up examination (p < 0.01). Ninety-four patients (63.5%) exhibited hypertensive phase (HP);
among them 73 patients (49.3%) experienced HP at 1 month and 21 (14.2%) at 2 months after the
operation. The cumulative probability of success according to KaplaneMeier life-table analysis was 78%
at 12 months and 43% at 3 years. There were no serious complications involving loss of visual acuity or
sight.
Conclusion: AGV implantation is an acceptable treatment for intractable glaucoma in high-risk Taiwanese
patients with few additional options.
Copyright  2012, The Ophthalmologic Society of Taiwan. Published by Elsevier Taiwan LLC. All rights
reserved.1. Introduction
Although trabeculectomy is regarded as the gold standard for
glaucoma surgery, the use of glaucoma drainage devices (GDDs) has
assumed an important role in the management of complicated and
intractable glaucoma.1,2 These devices can be used as the primary
surgical modality as well as a secondary procedure for those
patients with earlier failed surgery, such as trabeculectomy with or
without antimetabolite therapy.1e3 GDDs, including the Ahmed
glaucoma valve (AGV), facilitate aqueous drainage through a tube
inserted into the anterior or posterior chamber connected to
a posterior plate sutured into the episclera.1 The AGV was intro-
duced to the market in 1993; it is composed of a silicon drainage
tube (0.635 mm outer diameter, 0.317 mm inner diameter) and
a 184 mm2 polypropylene body (16 mm long  13 mm
wide  1.9 mm thick). The body consists of a specially tapered
chamber, with a large inlet to a small outlet, to create a venturi-ﬂow
effect and to provide resistance to aqueous ﬂow forming a one-waymology, Tri-Service General
i 114, Taiwan.
u).
e Ophthalmologic Society of Taiwoutlet designed to open at a pressure of 8 mmHg.1,3,4 Theoretically,
a valved GDD, such as the AGV, minimizes the incidence of post-
operative hypotony.4e6 but long-term studies on nonvalved GDDs
indicate better ﬁnal outcomes in reduced intraocular pressures
(IOPs).7 Thus far, no discrepancies have been observed in the
outcomes for GDD implants in Asian versus non-Asian eyes,
although Asians have been observed to have more severe tissue
reactions.5,8 The purpose of this study was to evaluate the clinical
experience of using AGV in Taiwanese patients with intractable
glaucoma. Differences in pre- and postoperative IOPs, success rates,
and surgical complications up to 3 years after surgery were
investigated.2. Methods
We reviewed the medical records of patients treated with AGV
implantation for intractable glaucoma uncontrolled by previous
medical or surgical interventions at the Department of Ophthal-
mology, Tri-Service General Hospital, Taipei, Taiwan, between
January 2004 and January 2008. For this retrospective interven-
tional case study, only patients with a minimum of 36 months of
follow-up were included in the study.an. Published by Elsevier Taiwan LLC. All rights reserved.
Table 1
Demographics.
Factors No. of patients (%)
Total patients 148
Sex (male/female) 84/64
Age (y) 54.2  6.8
Diagnosis
Primary glaucoma 29 (19.6%)
POAG 12 (8.1%)
ACG 11 (7.4%)
Congenital glaucoma 6 (4.1%)
Secondary glaucoma 119 (80.4%)
NVG 65 (43.9%)
Postkeratoplasty glaucoma 33 (22.3%)
Uveitic glaucoma 2 (4.5%)
Pseudophakic glaucoma 7 (4.7%)
Post-traumatic glaucoma 11 (7.4%)
No. of previous ocular surgeries
2 60 (40.5%)
1 68 (46.0%)
0 20 (13.5%)
Location of implant
Superotemporal 126 (85.1%)
Superonasal 22 (14.9%)
ACG ¼ angle-closure glaucoma; NVG ¼ neovascular glaucoma; POAG ¼ primary
open-angle glaucoma.
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institution. All surgerieswere performed by the same physician and
no other GDDs were used during the study period. Exclusion
criteria included the inability to be followed up for an extended
period of time postoperatively. The study was approved by the
hospital’s institutional review board. All patients gave written
informed consent for the surgical procedures. As the study was
a review of records developed during the course of medical treat-
ment, no informed consent was obtained for study inclusion. All
citizens in Taiwan are covered by Taiwan National Insurance Policy.
Under this health insurance system, the application of AGV has
assumed a place of last resort to manage complicated glaucoma
when a conventional trabeculectomy fails for a patient. In our
series, most of the patients had a history of failed trabeculectomy.
However, 20 patients who suffered from preoperative
IOP >40 mmHg with maximal medical treatments underwent
primary AGV implantations according to their own request.
Pre- and postoperative documentations of patient demo-
graphics for statistical analysis included age, gender, detailed clin-
ical history, results of slit-lamp examinations, IOP measurements
using the Goldmann applanation tonometer, and best-corrected
visual acuity (VA) measurement with a standard logMAR chart.
The distance VAwasmeasured according to the standard procedure
developed for the Early Treatment Diabetic Retinopathy Study.9
Under peribulbar or general anesthesia, we created a fornix-
based conjunctival ﬂap in the superotemporal or superonasal
quadrant between two adjacent rectus muscles. The rectus muscles
were identiﬁed, but no attempt was made to isolate them. After
a 3  3 mm2 triangular scleral ﬂap was created, the AGV (model S2
with a 185 mm2 polypropylene plate, New World Medical, Rancho
Cucamonga, CA, USA) was primed with a balanced saline solution
(BSS, Alcon, Fort Worth, TX, USA) to check the valve mechanism.
The polypropylene body was placed 8 mm posterior to the cor-
neoscleral limbus and sutured to the sclera with an 8-0 prolene
suture (Ethicon Inc., Somerville, NJ, USA). The tube was trimmed so
that the bevel faced the corneal endothelial surface and then
inserted into the anterior chamber through a needle track made
with a 23-gauge needle. A frozen human donor patch graft or
a commercially available scleral or pericardial patch graft (TranZ-
graft, Tissue Banks International, San Rafael, CA, USA) was placed
on the tube with the anterior edge adjacent to the limbus and
sutured to the sclerawith an 8-0 Vicryl suture, and then an anterior
chamber injection of 0.5 cm3 viscoelastic (Healon GV, Advanced
Medical Optics, Santa Ana, CA, USA) was performed to avoid early
hypotony. The conjunctiva was sutured to the limbus, and all eyes
received subconjunctival injections of steroids and antibiotics at
the end of the procedure. No adjunctive metabolite was used.
Postoperatively, topical Tobradex eye drops (Alcon, Fort Worth, TX,
USA) was prescribed and tapered slowly over 4e8 weeks. In addi-
tion, antiglaucoma medications were adjusted on the basis of the
IOP and clinical status of the operated eye. Patients were examined
at predetermined postoperative intervals: 1 day, 1 week, 2 weeks, 1
month, 3 months, 6 months, 9 months, 1 year, 2 years, and 3 years.
Slit-lamp examinations and assessments of VA, IOP, and compli-
cations were performed at each of these visits.
The primary outcome variable for success was postoperative IOP
control. Surgical success was deﬁned as an IOP <21 and >6 mmHg
without visually impairing complications, loss of light perception,
or the need for additional glaucoma surgery or AGV implant
removal. Hypotony was deﬁned as IOP <6 mmHg on any single
visit. For IOP >21 or <6 mmHg, treatment was attempted to lower
or raise the IOP, respectively, and the patient was re-examined
within a week; therefore, patients might have received additional
postoperative examinations. Success or failure was not deﬁned
until the patient had been seen at least twice after the 3e6-monthtime frame. The other outcome parameters were operative and
postoperative complications, including hyphema, shallow anterior
chamber, hypotony, choroidal effusion, graft failure, plate exposure
with leak, scleral patch graft or tube exposure, and tube blockage.
To assess differences in IOP and logMAR across multiple time
points, we used Student t test or Wilcoxon signed-rank tests.
KaplaneMeier life-table analysis was used to calculate survival
curves. All statistical assessments were two sided and were eval-
uated at the p < 0.05 level for signiﬁcant difference. Statistical
analyses were performed using SPSS 15.0 statistics software (SPSS
Inc., Chicago, IL, USA).
3. Results
Demographic and preoperative diagnoses for the 148 subjects
were indicated in Table 1. Patients ranged in age from 17 to 66 years
(mean 54.2 years), and the majority of the cases had undergone at
least one previous glaucoma ﬁltering surgery (86.5%). The most
common preoperative diagnoses were neovascular glaucoma
(43.9%) and postkeratoplasty glaucoma (22.3%). The majority of
patients had secondary glaucoma (80.4%). Themean follow-up time
was 38.3 months.
Table 2 represents the IOP data during the postoperative follow-
up period for all patients. The mean preoperative IOP was
32.6  4.7 mmHg. After implantation of AGV, IOP differed signiﬁ-
cantly over time (p < 0.01). Postoperatively, the median IOP
declined signiﬁcantly to 10.2  2.8 mmHg on Day 1 (p < 0.01),
rising slightly to 17.0  5.2 mmHg at the last follow-up (p < 0.01).
Moreover, at each time point, not only the IOP but also the number
of antiglaucoma medications decreased signiﬁcantly compared to
similar data preoperatively. However, we found that 94 patients
(63.5%) experienced the hypertensive phase (HP) after insertion of
the AGV in this study. Among them, 73 patients (49.3%) experi-
enced the HP at 1 month and 21 patients (14.2%) at 2 months after
the operation. The cumulative probability of success as per Kaplane
Meier life-table analysis (Fig. 1) was 78% at 12 months and 43% at 3
years. However, the success rate varied widely between patients
with different types of glaucoma (Table 3). Patients with primary
open-angle, angle-closure, and pseudophakic glaucoma had higher
Table 3
Comparison of success rates at the last follow-up after Ahmed valve implantation
between subgroups of different diagnosis.
Glaucoma diagnosis Eye (N) Success no. (%)
POAG 12 9 (75.0%)
ACG 11 7 (63.6%)
Congenital glaucoma 6 3 (50.0%)
Neovascular glaucoma 65 20 (30.8%)
PKP glaucoma 33 14 (51.5%)
Uveitic glaucoma 7 3 (42.9%)
Pseudophakic glaucoma 11 7 (63.6%)
Post-traumatic glaucoma 3 1 (33.3%)
ACG ¼ angle-closure glaucoma; PKP ¼ postkeratoplasty; POAG ¼ primary open-
angle glaucoma.
Table 2
IOP proﬁle before and after Ahmed Valve implant.
Visit IOP, Mean  SD
(mm Hg)
No. of antiglaucoma
medication
Baseline 32.6  4.7 3.4  1.0
Postoperative Day 1 10.2  2.8 0
Postoperative Week 1 8.3  4.2 0
Postoperative Month 1 11.6  5.2 0.3  0.5
Postoperative Month 3 14.6  4.6 0.5  0.6
Postoperative Month 6 15.2  5.1 1.1  0.7
Postoperative Month 12 14.8  3.6 0.8  0.6
Postoperative Month 24 16.2  5.8 1.1  0.7
Postoperative Month 36 17.0  5.2 1.4  0.9
In each postoperative time point, p < 0.01.
IOP ¼ intraocular pressure; SD ¼ standard deviation.
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traumatic glaucoma had lower success rates. Postoperative
complications were as follows: shallow anterior chamber (9.5%),
hyphema (7.4%), hypotony (2.7%), choroidal detachment (2.7%), and
encapsulation (8.1%). These complications occurred in the ﬁrst 3
months after surgery, as shown in Table 4. Late complications
observed were tube exposure (2%), tube occlusion (2%), retinal
detachment (0.6%), and delayed hyphema and vitreous hemorrhage
(9.5%). All 12 patients with encapsulated bleb during exploratory
bleb tapping underwent surgical revision with satisfactory results.
4. Discussion
Glaucoma surgery is performed when a further reduction of IOP
is needed despite maximal tolerated medical or laser treatment.
Valved and nonvalved GDDs have been used successfully to treat
a variety of glaucomas that are resistant to other therapies. In our
study, after the implantation of AGV, the mean IOP decreased
to10.2mmHg at Day 1 and 17mmHg at Year 3. This is comparable to
other studies showing a decreased IOP of 10e13 mmHg at Day 1
and 13e17 mmHg at Year 1.1e5 Success rates after AGV in refractory
glaucoma were variable in previous reports, but all showed a rela-
tive decline over time.1,3e6 In our study, we found a cumulative
probability of success for AGV implantation of 74% at 12 months
and 43% at 3 years, but the success rates varied widely among
patients with different types of glaucoma. These values were, in
general, lower than those published earlier. Huang et al3 reported
a cumulative probability of success of 87% at 1 year and 75% at 2
years, Topouzis et al10 reported 87% at 1 year and 82% at 2 years, andFig. 1. Cumulative probabilities of qualiﬁed success at 6, 12, 24, and 36 months after
Ahmed valve implantation, according to life-table analysis (KaplaneMeier plot), were
88%, 74%, 58%, and 43%, respectively. The median time of valve survival was 19.6  0.9
months.Lai et al8 showed a success rate of 73.8% in a study population of
98% Asian eyes and using similar criteria for success. The recent
report by Wishart et al11 also showed that the cumulative proba-
bility of survival at 1 and 4 years was 89.1% and 72.9%, respectively,
in a long-term follow-up. Even in pediatric glaucoma, Albis-Donado
et al12 showed a 96.9% survival rate at 6 months, 82.4% at 1 year,
78.7% at 2 years, 70% at 3 years, and 41.6% at 4 years. The relatively
low success rate in our study, 43% at 3 years, may be explained by
the inclusion of eyes with poorer prognosis. In Taiwan, all citizens
were covered by Taiwan National Insurance Policy; under this
unique health insurance system, the application of AGV has
assumed a place of last resort to manage complicated glaucoma
when a conventional trabeculectomy is contraindicated or not
available for a patient. For this reason, our series had more neo-
vascular and postkeratoplasty glaucoma patients. In general, AGV
has good prognosis in neovascular glaucoma patients, but this
group included patients with diabetes. Neovascular glaucoma is
a major ocular complication associated with diabetes mellitus.
Therefore, such patients have a higher probability of hyphema and
recurrent vitreous hemorrhage during follow-up, which might
result in failure owing to high IOP. This phenomenon was also
proved by Netland et al’s13 report, which demonstrated that the
success rate of AGV implantations in neovascular glaucoma was
73.1% at 1 year, dropping to 20.6% at 5 years. In fact, we found
neovascular glaucoma to be among those diagnoses with increased
likelihood of failure, along with uveitic and post-traumatic glau-
coma (Table 3).
The relatively young age in our study may also have affected our
success rate. Ayyala et al1 showed a cumulative probability of
success of 77% at 1 year in a study populationwith an average age of
64 years, and Huang et al’s3 study population averaged 60.9 years ofTable 4
Postoperative complications after Ahmed valve implantation.
Complication Number of
eyes, N (%)
Mean
postoperative
period (mo)
Treatment
Shallow anterior
chamber
14 (9.5%) 1 Chamber
reformation
Hypotony
(IOP < 6 mmHg)
4 (2.7%) 1 Observation
Hyphema 11 (7.4%) 1 Spontaneous
resolution
Tube exposure 3 (2%) 6 Scleral graft
Tube occlusion 3 (2%) 12 Surgical revision
Choroidal detachment 4 (2.7%) 2 Observation
Retinal detachment 1 (0.6%) 4 Observation
Encapsulation 12 (8.1%) 3 Surgical revision
Delayed hyphema and
vitreous hemorrhage
14(9.5%) 7 Observation
IOP ¼ intraocular pressure.
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of age. However, a recent retrospective study reviewed patients
who had Molteno implants inserted for neovascular glaucoma. The
authors concluded that age, sex, and postoperative IOP control did
not predict the survival.14 Another retrospective study for deter-
mining the intermediate-term efﬁcacy and safety of Baerveldt
glaucoma implants in Asian eyes with complicated glaucoma found
that preoperative IOP, length of follow-up, increasing age, and
number of operations performed before implant surgery were
correlated positively with failure after adjusting for gender.15 In
addition, in this study, we found that majority of patients (63.5%)
experienced an HP after insertion of the AGV. The HP, originally
reported by Molteno and Dempster,16 is a phenomenon in which
the bleb undergoes a striking sequence of change in the
surrounding tissue and may result in the formation of bleb ﬁbrosis
and in an inadequate control of IOP. According to previous studies,
the AGV is associated with a higher incidence of the HP, which
peaked in the ﬁrst month and stabilized by 6 months after the
operation.16 Regarding this point, this study showed comparable
results in that most incidences of the HP were exhibited in the ﬁrst
and second months after surgery. The higher incidence of the HP
could be related to the biomaterial, and the shape and consistency
of the end plate.17,18 It was suggested that the characteristics of the
AGV, being made of polypropylene with an extremely rigid
consistency, may enhance more micromotion in the postoperative
period and attract white cells and collagen to grow on the surface of
the plate, resulting in the formation of bleb ﬁbrosis and in the
subsequent elevation of IOP.17,18
The most common early postoperative complications in our
study were shallow anterior chamber (9.5%) and hyphema (7.4%).
Hyphema has been reported at 13.8e16.9% in AGV implantations
and typically resolves without any surgical intervention.7,14,19 The
reported incidence range of shallow anterior chamber with
hypotony is 3.5e27% for valved and nonvalved GDDs, with the
Ahmed valve at 3.5%, Molteno at 5%, and the Baerveldt at 16.5%.15
For hypotony alone, Taglia et al5 reported an incidence of 31% for
AGV implantation, 77% for Krupin, and 52% for Molteno, in a study
of 53 patients comparing these three devices. Differences between
these reports and our ﬁnding might be explained by the variety in
patients’ clinical status and surgical techniques. In our series, an
anterior chamber injection of 0.5 mL viscoelastic (Healon GV) was
performed to avoid early hypotony after suture. The incidence of
choroidal effusionwas 2.7%, which is comparable with an incidence
of 7e33% reported using different devices in varying series.2,3,14,20
Postoperative choroidal effusion often occurs because of lack of
resistance to aqueous outﬂow even in valve implants, especially
after excessive straining. No serious complications involving loss of
VA or sight were reported. Graft failure and scleral patch graft
exposure were minimal (2%), probably because of the use of the
frozen graft patch or lack of manipulation of the rectus muscles
during AGV installation. Corneal endothelial damage was a possible
complication after Ahmed valve insertion, and corneal trans-
plantation may be necessary in severe cases. Although we did not
collect data of corneal endothelial count in this series, yet no case of
corneal transplantation was needed throughout follow-up, which
may reﬂect the fact that no severe corneal damage happened in this
series.
In conclusion, AGV implantation seems to be a viable option for
Taiwanese patients with intractable glaucoma. In this series of 148patients, no serious adverse events were observed and the device
showed an overall cumulative probability of success of 78% at 1 year
and 43% at 3 years. AGV implantation seems to be an acceptable
treatment for intractable glaucoma or in high-risk patients with
few additional options.Acknowledgments
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